Type your tag names separated by a space and hit enter

The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.

Abstract

A 24-week, randomized, double-blind placebo-controlled study was carried out to test the feasibility of using omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in people with cognitive impairment and to explore its effects on cognitive function and general clinical condition in these participants. Twenty three participants with mild or moderate Alzheimer's disease and twenty three with mild cognitive impairment were randomized to receive omega-3 PUFAs 1.8 g/day or placebo (olive oil). The data of 35 (76%) participants with at least one post-treatment visit was analyzed. There were no severe adverse effects in either group and it suggests that omega-3 PUFAs were well tolerable in this population. The treatment group showed better improvement on the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus) than those in the placebo group over the 24 week follow-up (p=0.008). There was no significant difference in the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) change during follow-up in these two groups. However, the omega-3 fatty acids group showed significant improvement in ADAS-cog compared to the placebo group in participants with mild cognitive impairment (p=0.03), which was not observed in those with Alzheimer's disease. Higher proportions of eicosapentaenoic acid on RBC membranes were also associated with better cognitive outcome (p=0.003). Further studies should be considered with a larger-sample size, diet registration, higher dosages, comparisons between different combinations of PUFAs, and greater homogeneity of participants, especially those with mild Alzheimer's disease and mild cognitive impairment.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Department of Psychiatry, Taipei Medical University, Taipei, Taiwan.

    , , , , , ,

    Source

    MeSH

    Aged
    Aged, 80 and over
    Alzheimer Disease
    Cognition Disorders
    Double-Blind Method
    Eicosapentaenoic Acid
    Erythrocyte Membrane
    Fatty Acids, Omega-3
    Fatty Acids, Unsaturated
    Female
    Humans
    Male
    Neuropsychological Tests
    Psychiatric Status Rating Scales
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    18573585

    Citation

    Chiu, Chih-Chiang, et al. "The Effects of Omega-3 Fatty Acids Monotherapy in Alzheimer's Disease and Mild Cognitive Impairment: a Preliminary Randomized Double-blind Placebo-controlled Study." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 32, no. 6, 2008, pp. 1538-44.
    Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1538-44.
    Chiu, C. C., Su, K. P., Cheng, T. C., Liu, H. C., Chang, C. J., Dewey, M. E., ... Huang, S. Y. (2008). The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Progress in Neuro-psychopharmacology & Biological Psychiatry, 32(6), pp. 1538-44. doi:10.1016/j.pnpbp.2008.05.015.
    Chiu CC, et al. The Effects of Omega-3 Fatty Acids Monotherapy in Alzheimer's Disease and Mild Cognitive Impairment: a Preliminary Randomized Double-blind Placebo-controlled Study. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1538-44. PubMed PMID: 18573585.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. AU - Chiu,Chih-Chiang, AU - Su,Kuan-Pin, AU - Cheng,Tsung-Chi, AU - Liu,Hsing-Cheng, AU - Chang,Ching-Jui, AU - Dewey,Michael E, AU - Stewart,Robert, AU - Huang,Shih-Yi, Y1 - 2008/05/25/ PY - 2007/12/27/received PY - 2008/04/29/revised PY - 2008/05/17/accepted PY - 2008/6/25/pubmed PY - 2008/10/23/medline PY - 2008/6/25/entrez SP - 1538 EP - 44 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog. Neuropsychopharmacol. Biol. Psychiatry VL - 32 IS - 6 N2 - A 24-week, randomized, double-blind placebo-controlled study was carried out to test the feasibility of using omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in people with cognitive impairment and to explore its effects on cognitive function and general clinical condition in these participants. Twenty three participants with mild or moderate Alzheimer's disease and twenty three with mild cognitive impairment were randomized to receive omega-3 PUFAs 1.8 g/day or placebo (olive oil). The data of 35 (76%) participants with at least one post-treatment visit was analyzed. There were no severe adverse effects in either group and it suggests that omega-3 PUFAs were well tolerable in this population. The treatment group showed better improvement on the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus) than those in the placebo group over the 24 week follow-up (p=0.008). There was no significant difference in the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) change during follow-up in these two groups. However, the omega-3 fatty acids group showed significant improvement in ADAS-cog compared to the placebo group in participants with mild cognitive impairment (p=0.03), which was not observed in those with Alzheimer's disease. Higher proportions of eicosapentaenoic acid on RBC membranes were also associated with better cognitive outcome (p=0.003). Further studies should be considered with a larger-sample size, diet registration, higher dosages, comparisons between different combinations of PUFAs, and greater homogeneity of participants, especially those with mild Alzheimer's disease and mild cognitive impairment. SN - 0278-5846 UR - https://www.unboundmedicine.com/medline/citation/18573585/The_effects_of_omega_3_fatty_acids_monotherapy_in_Alzheimer's_disease_and_mild_cognitive_impairment:_a_preliminary_randomized_double_blind_placebo_controlled_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(08)00150-4 DB - PRIME DP - Unbound Medicine ER -